Are you Dr. Aisner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
12605 E 16th Ave
Aurora, CO 80045Phone+1 720-848-0000
Summary
- Dr. Dara Aisner, MD is a board certified pathologist in Aurora, Colorado. She is currently licensed to practice medicine in Colorado, Pennsylvania, and Maryland. She is affiliated with University of Colorado Hospital and UCHealth Memorial Hospital.
Education & Training
- University of Pennsylvania Health SystemFellowship, Molecular Genetic Pathology, 2009 - 2010
- National Institutes of Health Clinical CenterResidency, Pathology-Anatomic and Clinical, 2004 - 2008
- University of Texas Southwestern Medical SchoolClass of 2004
Certifications & Licensure
- CO State Medical License 2010 - 2025
- MD State Medical License 2006 - 2010
- PA State Medical License 2008 - 2010
- American Board of Pathology Pathology - Anatomic
- American Board of Pathology Clinical Informatics
- American Board of Pathology Pathology - Molecular Genetic
Publications & Presentations
PubMed
- 5 citationsNeoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.Collin M Blakely, Anatoly Urisman, Matthew A Gubens, Claire K Mulvey, Greg M Allen
Journal of Clinical Oncology. 2024-09-10 - 479 citationsLocal Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung CancerAndrew Weickhardt, Benjamin Scheier, Joseph Malachy Burke, Gregory N. Gan, Xian Lu
Journal of Thoracic Oncology. 2012-12-01 - 629 citationsNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman
Journal of the National Comprehensive Cancer Network. 2022-05-01
Authored Content
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase InhibitorsJanuary 2018
Press Mentions
- Pursuing Precision Oncology with World-Class Custom Bioinformatic PipelinesSeptember 23rd, 2024
- CU Anschutz Researchers Roll Out Antibody TestJune 9th, 2020
- CU Cell Technologies Shared Resource Makes COVID-19 Proteins for Research, Antibody TestingMay 29th, 2020
- Join now to see all
Professional Memberships
- Member